Myomo, Inc.

MYO

HealthcareMedical - DevicesAMEX

$0.85

Market Cap: $32.84M

Myomo, Inc. (MYO) Valuation Summary

Updated Apr 6, 2026 22:27

Model	Range	Fair Value	Upside
▸ Discounted Cash Flow
Revenue DCF 5Y	$0.05 – $6.90	$1.30	+85.7%
Revenue DCF 10Y	$0.08 – $14.89	$3.88	+452.1%
▸ Trading Multiples
EV/Revenue	$1.68 – $21.78	$2.85	+306.4%

Valuation History

DCF Analysis

Myomo, Inc. (MYO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$3.88

Market Price

$0.85

Upside / Downside

+356.5%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -35.2% to a target of 13.3% over 5 years, discounted at a WACC of 7.6%, Myomo, Inc. (MYO) has an intrinsic value of $3.88 per share (range: $0.08 – $14.89).

Key Assumptions

Current Operating Margin

-35.2%

Target Operating Margin

13.3%

WACC

7.6%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.5%

Target CapEx/Rev

6.0%

D&A/Revenue

3.2%

Tax Rate

21.0%

Operating margin fades linearly from the current level to the industry target over the 5-year projection. CapEx intensity fades from the historical average to a maintenance level (D&A × 1.5). Tax is only applied when operating income is positive (NOL shield).

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	44	8.0%	-25.5%	-11	-11	1	(1)	1	-12	-12
2027	50	13.6%	-15.8%	-8	-8	2	(2)	1	-9	-8
2028	70	38.4%	-6.1%	-4	-4	2	(2)	3	-8	-6
2029	85	21.8%	3.6%	3	2	3	(3)	2	-1	-0
2030	100	17.6%	13.3%	13	10	3	(4)	2	7	5
2031	126	26.4%	13.3%	17	13	4	(6)	4	7	5
2032	153	21.7%	13.3%	20	16	5	(8)	4	9	6
2033	179	17.1%	13.3%	24	19	6	(9)	4	11	6
2034	201	12.4%	13.3%	27	21	6	(11)	4	13	7
2035	217	7.7%	13.3%	29	23	7	(13)	2	14	7

Enterprise Value Bridge

Sum of PV(FCFF)9

Terminal Value (Gordon Growth at 3.0%)318

PV of Terminal Value159

Enterprise Value168

(–) Net Debt5

Equity Value162

(÷) Shares Outstanding42

Fair Value per Share$3.88

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
5.6%	$2	$5	$8	$12	$15
6.6%	$1	$3	$5	$8	$10
7.6%	$0	$2	$4	$6	$7
8.6%	$0	$1	$3	$4	$6
9.6%	$-0	$1	$2	$3	$5

Current price: $0.85. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 16.1% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Myomo, Inc. (MYO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$1.30

Market Price

$0.85

Upside / Downside

+52.9%

Verdict

Undervalued

Using a Revenue DCF model with operating margin convergence from -35.2% to a target of 13.3% over 5 years, discounted at a WACC of 7.6%, Myomo, Inc. (MYO) has an intrinsic value of $1.30 per share (range: $0.05 – $6.90).

Key Assumptions

Current Operating Margin

-35.2%

Target Operating Margin

13.3%

WACC

7.6%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.5%

Target CapEx/Rev

6.0%

D&A/Revenue

3.2%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	44	8.0%	-25.5%	-11	-11	1	(1)	1	-13	-12
2027	50	13.6%	-15.8%	-8	-8	2	(2)	1	-9	-8
2028	70	38.4%	-6.1%	-4	-4	2	(3)	3	-8	-7
2029	85	21.8%	3.6%	3	2	3	(4)	2	-2	-1
2030	100	17.6%	13.3%	13	10	3	(6)	2	5	4

Enterprise Value Bridge

Sum of PV(FCFF)-25

Terminal Value (Gordon Growth at 3.0%)118

PV of Terminal Value85

Enterprise Value60

(–) Net Debt5

Equity Value55

(÷) Shares Outstanding42

Fair Value per Share$1.30

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
5.6%	$-1	$1	$3	$5	$7
6.6%	$-1	$1	$2	$3	$5
7.6%	$-1	$0	$1	$2	$3
8.6%	$-1	$0	$1	$2	$3
9.6%	$-1	$-0	$1	$1	$2

Current price: $0.85. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 16.1% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$2.86

Market Price

$0.85

Upside / Downside

+236.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Myomo, Inc. (MYO) has a fair value of $2.86 based on 7 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Myomo, Inc.MYO	36	1.0x	0.9x
electroCore, Inc.ECOR	57	1.9x	1.4x
NeuroOne Medical Technologies CorporationNMTC	42	3.0x	3.1x
Precision Optics Corporation, Inc.POCI	31	1.6x	—
IGC Pharma, Inc.IGC	26	20.7x	1.2x
Milestone Scientific Inc.MLSS	23	2.5x	2.7x
Hyperion DeFi, Inc.HYPD	16	22.8x	17.9x
Nexalin Technology, Inc.NXL	7	22.4x	39.3x
Industry Median		3.0x	2.9x
(*) Revenue		41	44
= Enterprise Value		121	129
(-) Net Debt		5	5
Equity Value		116	124
(/) Outstanding shares		42	42
Fair Price		$3	$3

Selected Fair Value (avg of trailing + forward)

$2.86

+236.3%

Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.

Model

Range

Fair Value

Upside

▸ Discounted Cash Flow

Revenue DCF 5Y

$0.05 – $6.90

$1.30

+85.7%

Revenue DCF 10Y

$0.08 – $14.89

$3.88

+452.1%

▸ Trading Multiples

EV/Revenue

$1.68 – $21.78

$2.85

+306.4%

DCF Analysis

Myomo, Inc. (MYO) Revenue DCF (5Y)

REVENUE DCF FAIR VALUE

$3.88

Market Price

$0.85

Upside / Downside

+356.5%

Verdict

Undervalued

Key Assumptions

Current Operating Margin

-35.2%

Target Operating Margin

13.3%

WACC

7.6%

Terminal Growth Rate

3.0%

Historical CapEx/Rev

2.5%

Target CapEx/Rev

6.0%

D&A/Revenue

3.2%

Tax Rate

21.0%

Margin Convergence Projection

USD in millions. Mid-year discounting convention.

Year	Revenue	Growth	Op Margin	Op Income	NOPAT	D&A	CapEx	ΔNWC	FCFF	PV(FCFF)
2026	44	8.0%	-25.5%	-11	-11	1	(1)	1	-12	-12
2027	50	13.6%	-15.8%	-8	-8	2	(2)	1	-9	-8
2028	70	38.4%	-6.1%	-4	-4	2	(2)	3	-8	-6
2029	85	21.8%	3.6%	3	2	3	(3)	2	-1	-0
2030	100	17.6%	13.3%	13	10	3	(4)	2	7	5
2031	126	26.4%	13.3%	17	13	4	(6)	4	7	5
2032	153	21.7%	13.3%	20	16	5	(8)	4	9	6
2033	179	17.1%	13.3%	24	19	6	(9)	4	11	6
2034	201	12.4%	13.3%	27	21	6	(11)	4	13	7
2035	217	7.7%	13.3%	29	23	7	(13)	2	14	7

Enterprise Value Bridge

Sum of PV(FCFF)9

Terminal Value (Gordon Growth at 3.0%)318

PV of Terminal Value159

Enterprise Value168

(–) Net Debt5

Equity Value162

(÷) Shares Outstanding42

Fair Value per Share$3.88

Sensitivity Analysis — WACC × Target Operating Margin

WACC \ Target Op. Margin	7.3%	10.3%	13.3%	16.3%	19.3%
5.6%	$2	$5	$8	$12	$15
6.6%	$1	$3	$5	$8	$10
7.6%	$0	$2	$4	$6	$7
8.6%	$0	$1	$3	$4	$6
9.6%	$-0	$1	$2	$3	$5

Current price: $0.85. Green = undervalued, Red = overvalued.

Working Capital Assumption

Net Working Capital is modeled at 16.1% of revenue (historical average of receivables + inventory − payables). Changes in NWC (ΔNWC) are computed year-over-year and subtracted from free cash flow.

Trading Multiples

Fair Value

$2.86

Market Price

$0.85

Upside / Downside

+236.3%

Verdict

Undervalued

Using the industry peer median EV/Revenue multiple (trailing + forward), Myomo, Inc. (MYO) has a fair value of $2.86 based on 7 comparable companies in the Medical - Devices industry.

EV/Revenue Valuation — Medical - Devices

USD in millions except Fair Price. Subject company highlighted.

	Mkt Cap ($M)	Trailing EV/Revenue	Forward EV/Revenue
Myomo, Inc.MYO	36	1.0x	0.9x
electroCore, Inc.ECOR	57	1.9x	1.4x
NeuroOne Medical Technologies CorporationNMTC	42	3.0x	3.1x
Precision Optics Corporation, Inc.POCI	31	1.6x	—
IGC Pharma, Inc.IGC	26	20.7x	1.2x
Milestone Scientific Inc.MLSS	23	2.5x	2.7x
Hyperion DeFi, Inc.HYPD	16	22.8x	17.9x
Nexalin Technology, Inc.NXL	7	22.4x	39.3x
Industry Median		3.0x	2.9x
(*) Revenue		41	44
= Enterprise Value		121	129
(-) Net Debt		5	5
Equity Value		116	124
(/) Outstanding shares		42	42
Fair Price		$3	$3

Selected Fair Value (avg of trailing + forward)

$2.86

+236.3%